In adults newly diagnosed with a type of blood cancer called core-binding factor acute myeloid leukemia (CBF-AML), genetic mutations present before treatment do not…
Blood cancer
AML World Awareness Day, an annual effort to educate people about acute myeloid leukemia (AML), is coming up on April 21, and the advocacy…
The U.S. Food and Drug Administration (FDA) has given the green light for a first-in-human clinical trial to test a new cell therapy for acute…
Caris Life Sciences has developed a genetic test that aims to simplify care for people with a group of blood cancers known as…
Merck is set to acquire Terns Pharmaceuticals in a $6.7 billion deal aimed at expanding its oncology pipeline, including an experimental treatment for chronic…
Tempus AI, a technology company focused on advancing precision medicine using artificial intelligence (AI), has announced a strategic collaboration with the advocacy organization…
Sellas Life Sciences is seeking people with newly diagnosed acute myeloid leukemia (AML) for a clinical trial testing its experimental anticancer therapy SLS009…
Treatment with the targeted therapy Venclexta (venetoclax) in combination with chemotherapy led to disease remission for most people with hard-to-treat acute myeloid leukemia (AML) in…
Early results from the Phase 2/3 MIRACLE clinical trial suggest that the experimental chemotherapy drug annamycin may offer meaningful benefit as a second-line treatment for…
The U.S. Food and Drug Administration (FDA) has approved the combination of two oral therapies, Venclexta (venetoclax) and Calquence (acalabrutinib), for previously untreated adults with…
